Reno-pancreas protective effects of Spirulina platensis in alloxan induced diabetic rats.

A large variety of herbal elements are employed in the treatment of diabetes for their better efficacy and safety compare to synthetic drugs. In this experiment Spirulina platensis was used to evaluate the antidiabetic, kidney & pancreas injury protective potential in alloxan induced diabetic rats. Male Long Evans rats having six weeks of age were used for the experiment. Diabetes was induced by intraperitoneal injection of alloxan @ 150 mg/kg and experiment was carried out for a period of six weeks. The study was conducted by dividing the animal into three groups (n=7 rats in each group) indicated as with Group-A (healthy control); Group-B (diabetic control); Group-C (Diabetic rats treated with Spirulina platensis @ 400 mg/kg). Spirulina platensis reduced blood glucose significantly (P<0.01) and improved the body weight losses significantly (P<0.05) compared to diabetic rats after six weeks treatment. The histopathological alteration was observed in the kidney of diabetic rats which was characterized by glomerular hypertrophy, tubular necrosis and interstitial fibrosis. Marked improvements in the histopathological change were noticed in the kidneys of diabetic rats treated with Spirulina platensis. Pancreatic injury was produced by alloxan induction in rats characterized by destruction of the pancreatic ß cells mostly in the central portion of the islets of langerhans and lymphocytic infiltrations, atrophy, and interstitial fibrosis, which were suppressed by Spirulina platensis. In addition, alloxan induced diabetic rats showed increased plasma lipid peroxidase level which was ameliorated by Spirulina platensis treatment. Along with previous report the anticipated results would concluded that Spirulina platensis having antioxidant compounds could protect renal tissues damage, stimulate regeneration and reactivation of pancreatic ß- cells in alloxan induced diabetic rats.

Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.

Although beneficial antihypertensive and antialbuminuric effects of steroidal mineralocorticoid receptor (MR) antagonists have been shown, the use of these drugs has been clinically limited in diabetic kidney disease (DKD) because of the high incidence of side effects. Here, we aimed to examine the effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone, on blood pressure and renal injury in high salt-treated type 2 diabetic KK-Ay mice, a model of human hypertensive DKD. KK-Ay mice were treated with a normal salt diet (NS: 0.3% NaCl, n = 5), high salt diet (HS: 4% NaCl, n = 8), HS + esaxerenone (1 mg/kg/day, p.o., n = 8), or HS + spironolactone, a steroidal non-selective MR antagonist (20 mg/kg/day, p.o., n = 7) for 8 weeks. Renal tissue oxidative stress was evaluated by dihydroethidium florescence intensity. HS-treated diabetic KK-Ay mice showed higher blood pressure and severe albuminuria, glomerular injury, tubulointerstitial fibrosis, renal inflammation, and oxidative stress than NS-treated diabetic KK-Ay mice. Treatment with esaxerenone or spironolactone decreased blood pressure to a similar extent in HS-treated KK-Ay mice. Conversely, esaxerenone elicited a greater attenuation of albuminuria, glomerular injury, tubulointerstitial fibrosis, and renal inflammation than spironolactone, which were associated with reduction in renal oxidative stress. These data indicate for the first time that a nonsteroidal MR antagonist elicits renoprotective effects in DKD mice.